7.37
-0.09 (-1.27%)
| Previous Close | 7.46 |
| Open | 7.43 |
| Volume | 589,072 |
| Avg. Volume (3M) | 1,081,140 |
| Market Cap | 574,059,904 |
| Price / Earnings (TTM) | 3.59 |
| Price / Earnings (Forward) | 46.51 |
| Price / Sales | 1.54 |
| Price / Book | 1.30 |
| 52 Weeks Range | |
| Earnings Date | 16 Nov 2026 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CorMedix Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 0.14 |
Select this tab to load the latest available analysis.
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Oberweis Asset Management Inc/ | 30 Jun 2026 | 1,323,915 |
| Pacer Advisors, Inc. | 30 Jun 2026 | 633,978 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |